These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21566437)

  • 1. [Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
    Sugisaki T; Kawakami K; Nemoto M; Kawata K; Ishibashi M; Fujiki Y; Mishima Y; Yokoyama M; Takahashi S; Hatake K; Hama T
    Gan To Kagaku Ryoho; 2011 May; 38(5):783-7. PubMed ID: 21566437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters.
    Mitsuhashi H; Suemaru K; Li B; Cui R; Araki H
    Eur J Pharmacol; 2006 Dec; 551(1-3):152-5. PubMed ID: 17046745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Effect of Polaprezinc, a Zinc-L-carnosine, Against Chemotherapy-induced Oral Mucositis in Pediatric Patients Undergoing Autologous Stem Cell Transplantation.
    Funato M; Ozeki M; Suzuki A; Ishihara M; Kobayashi R; Nozawa A; Yasue S; Endo-Ohnishi S; Fukao T; Itoh Y
    Anticancer Res; 2018 Aug; 38(8):4691-4697. PubMed ID: 30061237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation.
    Hayashi H; Kobayashi R; Suzuki A; Ishihara M; Nakamura N; Kitagawa J; Kanemura N; Kasahara S; Kitaichi K; Hara T; Tsurumi H; Moriwaki H; Itoh Y
    Anticancer Res; 2014 Dec; 34(12):7271-7. PubMed ID: 25503160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polaprezinc on oral mucositis, irradiation period, and time to discharge in patients with head and neck cancer.
    Suzuki A; Kobayashi R; Shakui T; Kubota Y; Fukita M; Kuze B; Aoki M; Sugiyama T; Mizuta K; Itoh Y
    Head Neck; 2016 Sep; 38(9):1387-92. PubMed ID: 27002591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New medicinal treatment for severe gingivostomatitis.
    Katayama S; Ohshita J; Sugaya K; Hirano M; Momose Y; Yamamura S
    Int J Mol Med; 1998 Dec; 2(6):675-9. PubMed ID: 9850735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
    Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
    J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer.
    Watanabe T; Ishihara M; Matsuura K; Mizuta K; Itoh Y
    Int J Cancer; 2010 Oct; 127(8):1984-90. PubMed ID: 20104529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of polaprezinc as a preventive drug for radiation-induced stomatitis].
    Masayuki F; Norihiko K; Keita T; Miwa I; Masayuki I; Toshihiko I; Hiromi F; Chikaaki M; Norio N
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Mar; 62(4):144-50. PubMed ID: 12043217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the pharmaceutical stability of polaprezinc/sodium alginate gargle solution containing lidocaine].
    Myotoku M; Matsuyama T; Umetani R; Nakamura S; Oka T; Kitade N; Urashima Y; Hirotani Y
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):207-10. PubMed ID: 25743140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy.
    Hayashi H; Kobayashi R; Suzuki A; Yamada Y; Ishida M; Shakui T; Kitagawa J; Hayashi H; Sugiyama T; Takeuchi H; Tsurumi H; Itoh Y
    Med Oncol; 2016 Aug; 33(8):91. PubMed ID: 27418192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digestive symptoms as side effects of combination chemotherapy of docetaxel, nedaplatin and 5-fluorouracil for head and neck cancer.
    Uchiyama K; Iwabuchi H; Yamada M; Sugiyama K; Nakayama S
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1659-64. PubMed ID: 23152015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer].
    Fukui T; Itoh Y; Orihara M; Yoshizawa K; Takeda H; Kawada S; Yoshioka T
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2597-601. PubMed ID: 22189225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of advanced head and neck cancer by TPF].
    Watanabe A; Taniguchi M; Tsujizakae H; Toyama T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1240-3. PubMed ID: 20684089
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.